EMA's Walks Fine Line On How It Will Publish Clinical Study Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
In finalizing its policy on publishing clinical study reports, EMA stresses redactions of commercially confidential information will be rare, but critics still say it is favoring the pharma industry.
You may also be interested in...
EMA Loses Key Round In Court Battle For Flagship Transparency Policy
The European Medicines Agency may be forced to re-examine whether clinical trial data should be regarded as presumptively confidential under its access to documents policy.
European Notebook: Data Transparency And Adaptive Licensing Move Forward
More clinical trials move to Denmark, Sanofi’s Viehbacher moves to Boston, and analysts suggest thwarted Pfizer’s next strategic move may be to use contingent value rights in a future attempt for AstraZeneca, plus more in this month’s notebook.
MEPs Pass Clinical Trials Laws But Implementation Will Be Troublesome
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.